'Assay development' presentation slideshows

US/Ireland Emerging Technologies, Univ. of Massachusetts, Lowell, Oct 1 9 -2 0 th . , 2009 .

470 views • 32 slides

Assay Design and Quality Control in HTS and Lead Optimisation.

394 views • 22 slides

Feasibility of HIF stabilization and activity in tumor cells

Feasibility of HIF stabilization and activity in tumor cells. Florian Stuker, Katerina Dikaiou, Steffi Lehmann, Markus Rudin. WP6/7: Applications to murine tumor models: tool development and therapy assessment I. Application: assay development (hypoxia cascade)

209 views • 20 slides

Pronucleon TM A mplified M isfolded P rotein D iagnostic Assay (AMP-D)

Pronucleon TM A mplified M isfolded P rotein D iagnostic Assay (AMP-D). Kenton L. Lohman, Ph.D. VP Assay Development Adlyfe Inc ., Rockville, MD. Amplified Misfolded Protein Diagnostic (AMP-D) Assay. Exploits the basis of the misfolded protein disease - - - protein conformational change

218 views • 11 slides

103 views • 9 slides

Phase 0 Key Points

Phase 0 Key Points . Are Phase 0 studies feasible? Phase 0 recruitment is feasible but depends on patient altruism and prior physician-patient relationship. Statistical methodology is more challenging in Phase 0 trials, which involve novel PD endpoints and small number of samples.

244 views • 8 slides

Phase 0 Key Points

Phase 0 Key Points. Are Phase 0 studies feasible? Phase 0 recruitment is feasible but depends on patient altruism and prior physician-patient relationship. Statistical methodology is more challenging in Phase 0 trials, which involve novel PD endpoints and small number of samples.

92 views • 8 slides